Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single‐blinded cross‐over trial

Harbo, Thomas; Andersen, Henning; Heß, Alexander; Hansen, Klaus; Sindrup, Søren Hein; Jakobsen, Johannes

doi:10.1111/j.1468-1331.2009.02568.x

Cited by 148 publications

(138 citation statements)

References 32 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…The abstracts and/or full texts of the 34 studies were retrieved, evaluated in detail and filtered according to the eligibility criteria. After this stage five studies were left for inclusion in the review [27][28][29][30][31]. A hand search of the references of relevant citations resulted in an additional study being included in the final review [32].…”

Section: Search Resultsmentioning

confidence: 99%

“…The majority (4/6) of the studies concluded that patients had demonstrated a preference for SC drug administration [27][28][29][30] proportions ranged from 44%-91%. Only one study reported that patients preferred IV drug delivery [32] and another found no difference in patient preference for either method [31].…”

Section: Patient Preferencesmentioning

confidence: 99%

“…The study by Harbo et al (2009) [29] was conducted on patients with MMN. Patients were randomised to either receive SC or IV immunoglobulin (Ig) of equal doses.…”

Section: Patient Preferencesmentioning

confidence: 99%

See 2 more Smart Citations

Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review

Stoner

Harder

Fallowfield

et al. 2014

Patient

118

102

View full text Add to dashboard Cite

show abstract

Section: Search Resultsmentioning

confidence: 99%

Section: Patient Preferencesmentioning

confidence: 99%

See 1 more Smart Citation

Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review

Stoner

Harder

Fallowfield

et al. 2014

Patient

118

102

View full text Add to dashboard Cite

show abstract

“…A randomized, single-blinded, crossover study was conducted in 9 patients responsive to IVIG and assessed by the dynamometric strength of affected muscles and the SF-36 quality-oflife questionnaire [83]. IVIG and SCIG were equally effective, the mean change in muscle strength after SCIG being 3.6 % versus 4.3 % after IVIG.…”

Section: Subcutaneous Immunoglobulinmentioning

confidence: 99%

Immunotherapy in Peripheral Neuropathies

Léger¹,

Guimarães‐Costa²,

Muntean³

2016

Neurotherapeutics

View full text Add to dashboard Cite

Immunotherapy has been investigated in a small subset of peripheral neuropathies, including an acute one, Guillain-Barré syndrome, and 3 chronic forms: chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and neuropathy associated with IgM anti-myelin-associated glycoprotein. Several experimental studies and clinical data are strongly suggestive of an immune-mediated pathogenesis. Either cell-mediated mechanisms or antibody responses to Schwann cell, compact myelin, or nodal antigens are considered to act together in an aberrant immune response to cause damage to peripheral nerves. Immunomodulatory treatments used in these neuropathies aim to act at various steps of this pathogenic process. However, there are many phenotypic variants and, consequently, there is a significant difference in the response to immunotherapy between these neuropathies, as well as a need to improve our knowledge and long-term management of chronic forms.

show abstract

“…First case reports in CIDP and MMN suggest that scIg is effective [Lee et al 2008;Köller et al 2006]. The results of randomized trials with scIg are expected to be published next year [Harbo et al 2008].…”

Section: Conclusion and Future Prospectsmentioning

confidence: 99%

Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins

Stangel

2008

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Since the incidental discovery in 1981 that intravenous immunoglobulins (IVIg) are immunomodulatory, they have been investigated in a large number of putative autoimmune diseases. This has led to licensing for idiopathic thrombocytopenic purpura, Kawasaki disease, and in neurological disorders for Guillain-Barré syndrome (GBS). Although not licensed, randomized controlled trials have also shown IVIg efficacy in other neuroimmunological diseases such as multifocal motor neuropathy (MMN), chronic inflammatory demyelinating neuropathy (CIDP), myasthenia gravis, dermatomyositis, and stiff-person syndrome. However, other indications are currently being explored including Alzheimer's disease, postpolio syndrome, and narcolepsy. There are even reports from experimental studies in stroke. The results of recently published clinical trials in both the classical neuroimmunological disorders as well as for new indications are reported and their role in clinical practice is discussed.

show abstract

Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single‐blinded cross‐over trial

Abstract: In MMN, short-term subcutaneous infusion of immunoglobulin is feasible, safe and as effective as intravenous infusion. Subcutaneous administration is an alternative option that adds flexibility to the treatment schedule.

Cited by 148 publications

References 32 publications

Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review

Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review

Immunotherapy in Peripheral Neuropathies

Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins

Contact Info

Product

Resources

About